OGN – Organon & Co.
Organon & Co.OGN
$15.49Name : Organon & Co.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $3,989,279,232.00
EPSttm : 3.33
Organon & Co.
$15.49
1.27%$0.2Float Short %
6.46
Margin Of Safety %
33
Put/Call OI Ratio
0.44
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
0.25
Price
15.49
Target Price
20.5
Analyst Recom
2.6
Performance Q
2.58
Relative Volume
1.05
Beta
0.72
Ticker: OGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | OGN | 16.41 | 0.66 | 0.03 | 32711 |
| 2025-01-24 | OGN | 15.97 | 0.56 | 0.59 | 36756 |
| 2025-01-27 | OGN | 16.25 | 0.55 | 0.41 | 37333 |
| 2025-01-28 | OGN | 16.06 | 0.55 | 0.24 | 37918 |
| 2025-01-29 | OGN | 15.84 | 0.54 | 2.22 | 38544 |
| 2025-01-30 | OGN | 15.97 | 0.55 | 0.76 | 38934 |
| 2025-01-31 | OGN | 15.56 | 0.55 | 1.02 | 39854 |
| 2025-02-03 | OGN | 14.91 | 0.57 | 1.47 | 40595 |
| 2025-02-04 | OGN | 14.94 | 0.59 | 1.30 | 41043 |
| 2025-02-05 | OGN | 15.3 | 0.59 | 1.19 | 41330 |
| 2025-02-06 | OGN | 14.9 | 0.59 | 0.97 | 41845 |
| 2025-02-07 | OGN | 14.63 | 0.60 | 0.49 | 42203 |
| 2025-02-10 | OGN | 15.05 | 0.60 | 0.41 | 42644 |
| 2025-02-11 | OGN | 14.95 | 0.60 | 5.23 | 43048 |
| 2025-02-12 | OGN | 14.7 | 0.65 | 0.76 | 44742 |
| 2025-02-13 | OGN | 16.33 | 0.66 | 0.13 | 47525 |
| 2025-02-14 | OGN | 15.27 | 0.56 | 0.02 | 51483 |
| 2025-02-18 | OGN | 15.49 | 0.45 | 0.33 | 59555 |
| 2025-02-19 | OGN | 15.3 | 0.43 | 1.57 | 60150 |
| 2025-02-20 | OGN | 15.66 | 0.44 | 0.30 | 59915 |
| 2025-02-21 | OGN | 15.49 | 0.44 | 0.78 | 60031 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | OGN | 16.41 | -1.3 | - | 4.10 |
| 2025-01-24 | OGN | 15.97 | -1.3 | - | 4.10 |
| 2025-01-27 | OGN | 16.24 | -1.3 | - | 4.10 |
| 2025-01-28 | OGN | 16.07 | -1.3 | - | 4.10 |
| 2025-01-29 | OGN | 15.84 | -1.3 | - | 4.10 |
| 2025-01-30 | OGN | 15.97 | -1.3 | - | 4.10 |
| 2025-01-31 | OGN | 15.56 | -1.6 | - | 4.10 |
| 2025-02-03 | OGN | 14.91 | -1.6 | - | 4.10 |
| 2025-02-04 | OGN | 14.94 | -1.6 | - | 4.10 |
| 2025-02-05 | OGN | 15.32 | -1.6 | - | 4.10 |
| 2025-02-06 | OGN | 14.89 | -1.6 | - | 4.10 |
| 2025-02-07 | OGN | 14.62 | -1.6 | - | 4.10 |
| 2025-02-10 | OGN | 15.04 | -1.6 | - | 4.10 |
| 2025-02-11 | OGN | 14.95 | -1.6 | - | 4.10 |
| 2025-02-12 | OGN | 14.69 | -1.6 | - | 4.10 |
| 2025-02-13 | OGN | 16.32 | -1.6 | - | 4.10 |
| 2025-02-14 | OGN | 15.28 | -1.6 | - | 4.10 |
| 2025-02-18 | OGN | 15.48 | -26.0 | - | 3.89 |
| 2025-02-19 | OGN | 15.29 | -26.0 | - | 3.89 |
| 2025-02-20 | OGN | 15.67 | -26.0 | - | 3.89 |
| 2025-02-21 | OGN | 15.49 | -26.0 | - | 3.89 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | OGN | 0.00 | 1.03 | 7.14 |
| 2025-01-24 | OGN | 0.00 | 1.03 | 7.14 |
| 2025-01-27 | OGN | 0.00 | -0.62 | 7.14 |
| 2025-01-28 | OGN | 0.00 | -0.62 | 7.09 |
| 2025-01-29 | OGN | 0.00 | -0.62 | 7.09 |
| 2025-01-30 | OGN | 0.00 | -0.62 | 7.09 |
| 2025-01-31 | OGN | 0.00 | -0.62 | 7.09 |
| 2025-02-03 | OGN | 0.00 | 5.10 | 7.09 |
| 2025-02-04 | OGN | 0.00 | 5.10 | 7.09 |
| 2025-02-05 | OGN | 0.00 | 5.10 | 7.09 |
| 2025-02-06 | OGN | 0.00 | 5.10 | 7.09 |
| 2025-02-07 | OGN | 0.00 | 5.10 | 7.09 |
| 2025-02-10 | OGN | 0.00 | 5.44 | 7.10 |
| 2025-02-11 | OGN | 0.00 | 5.44 | 7.10 |
| 2025-02-12 | OGN | 0.00 | 5.44 | 6.46 |
| 2025-02-13 | OGN | 0.00 | 5.44 | 6.46 |
| 2025-02-14 | OGN | 0.00 | 5.44 | 6.46 |
| 2025-02-18 | OGN | 0.00 | 4.51 | 6.46 |
| 2025-02-19 | OGN | 0.00 | 4.51 | 6.46 |
| 2025-02-20 | OGN | 0.00 | 4.51 | 6.46 |
| 2025-02-21 | OGN | 0.00 | 4.51 | 6.46 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.9
Avg. EPS Est. Next Quarter
0.9
Insider Transactions
Institutional Transactions
4.51
Beta
0.72
Average Sales Estimate Current Quarter
1547
Average Sales Estimate Next Quarter
1564
Fair Value
20.58
Quality Score
87
Growth Score
71
Sentiment Score
82
Actual DrawDown %
60.8
Max Drawdown 5-Year %
Target Price
20.5
P/E
4.65
Forward P/E
3.69
PEG
3.32
P/S
0.62
P/B
8.09
P/Free Cash Flow
5.34
EPS
3.33
Average EPS Est. Cur. Y
3.89
EPS Next Y. (Est.)
4.14
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
13.49
Relative Volume
1.05
Return on Equity vs Sector %
244.7
Return on Equity vs Industry %
236.9
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.23
EBIT Estimation
Organon & Co.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 10000
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
stock quote shares OGN – Organon & Co. Stock Price stock today
news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGN – Organon & Co. yahoo finance google finance
stock history OGN – Organon & Co. invest stock market
stock prices OGN premarket after hours
ticker OGN fair value insiders trading